“Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s617, https://doi.org/10.25251/gf6mb511.